Stage III and IV melanoma patients are routinely tested for the BRAF gene mutation, a known oncogene for melanoma. Recently, Vemurafenib, a new FDA-approved drug, was found to be highly effective for patients with previously treated metastatic melanoma that have the BRAF mutation, but patients may develop resistance to this drug. So, researchers at the Moffitt Cancer Center tested six different models of Vemurafenib resistance against an inhibitor called XL888. They found that the inhibitor...
↧
